Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 256

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice

Open access
Gomez, Delphine, Baylis, Richard A., Durgin, Brittany G., Newman, Alexandra A. C., Alencar, Gabriel F., Mahan, Sidney, St. Hilaire, Cynthia, Müller, Werner, Waisman, Ari, Francis, Sheila E., Pinteaux, Emmanuel, Randolph, Gwendalyn J., Gram, Hermann, Owens, Gary K. · 2018 · Nature Medicine

Abstract

Despite decades of research, our understanding of the processes controlling late-stage atherosclerotic plaque stability remains poor. A prevailing hypothesis is that reducing inflammation may improve advanced plaque stability, as recently tested in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, in which post-myocardial infarction subjects were treated with an IL-1β antibody. Here, we performed intervention studies in which smooth muscle cell (SMC) lineage-tracing Apoe-/- mice with advanced atherosclerosis were treated with anti-IL-1β or IgG control antibodies. Surprisingly, we found that IL-1β antibody treatment between 18 and 26 weeks of Western diet feeding induced a marked reduction in SMC and collagen content, but increased macrophage numbers in the fibrous cap. Moreover, although IL-1β antibody treatment had no effect on lesion size, it completely inhibited beneficial outward remodeling. We also found that SMC-specific knockout of Il1r1 (encoding IL-1 receptor type 1) resulted in smaller lesions nearly devoid of SMCs and lacking a fibrous cap, whereas macrophage-selective loss of IL-1R1 had no effect on lesion size or composition. Taken together, these results show that IL-1β has multiple beneficial effects in late-stage murine atherosclerosis, including promotion of outward remodeling and formation and maintenance of an SMC- and collagen-rich fibrous cap. Interleukin-1β promotes an atheroprotective phenotype in late-stage lesions of mice, suggesting the possibility of deleterious effects of interleukin-1β blockade in the setting of myocardial infarction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0124-5

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 256

Metadata

Authors
Gomez, D., Baylis, R. A., Durgin, B. G., Newman, A. A. C., Alencar, G. F., Mahan, S., St. Hilaire, C., Müller, W., Waisman, A., Francis, S. E., Pinteaux, E., Randolph, G. J., Gram, H., & Owens, G. K.
Venue
Nature Medicine
Published
2018-07-23
Volume
24
Issue
9
Pages
1418-1429
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2885002489
Cited by
256
References
62
FWCI
9.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice. https://app.cochat.ai/papers/10.1038/s41591-018-0124-5
The paper
Gomez, D., Baylis, R. A., Durgin, B. G., Newman, A. A. C., Alencar, G. F., Mahan, S., St. Hilaire, C., Müller, W., Waisman, A., Francis, S. E., Pinteaux, E., Randolph, G. J., Gram, H., & Owens, G. K. (2018). Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice. Nature Medicine. https://doi.org/10.1038/s41591-018-0124-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.